High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects

Journal of Virology

Volumn 87, Issue 16, 2013, Pages 9148-9158

  Iglesias Ussel, Maria ^a   Vandergeeten, Claire ^b   Marchionni, Luigi ^c   Chomont, Nicolas ^b   Romerio, Fabio ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VGTI Florida   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; CHEMOKINE RECEPTOR; CYTOKINE RECEPTOR; INTEGRIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS DNA; VIRUS RNA;

ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL ASSAY; CELL LEVEL; CELL MEMBRANE STEADY POTENTIAL; CELL SELECTION; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; FLOW CYTOMETRY; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; LATENT VIRUS INFECTION; MEMORY CELL; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SYNTHESIS; UPREGULATION; VIRUS IDENTIFICATION;

ANTIGENS, CD2; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; PROVIRUSES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84881249519     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01297-13     Document Type: Article

References (85)

1. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM. 2003. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41:4531-4536.
2. Cohen Stuart JW, Wensing AM, Kovacs C, Righart M, de Jong D, Kaye S, Schuurman R, Visser CJ, Boucher CA. 2001. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J. Acquir. Immune Defic. Syndr. 28:105-113.
3. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Gunthard HF, Richman DD, Wong JK. 2001. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 286:171-179.
4. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF. 2001. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc. Natl. Acad. Sci. U. S. A. 98:13288-13293.
5. Choudhary SK, Margolis DM. 2011. Curing HIV: pharmacologic approaches to target HIV-1 latency. Annu. Rev. Pharmacol. Toxicol. 51:397-418.
6. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. 2009. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat. Rev. Microbiol. 7:798-812.
7. Dahl V, Josefsson L, Palmer S. 2010. HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral Res. 85:286-294.
8. Iglesias-Ussel MD, Romerio F. 2011. HIV reservoirs: the new frontier. AIDS Rev. 13:13-29.
9. Tyagi M, Romerio F. 2011. Models of HIV-1 persistence in the CD4+ T cell compartment: past, present and future. Curr. HIV Res. 9:579-587.
10. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, YassineDiab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15:893-900.
11. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485.
12. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366:549-555.
13. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. 2009. The challenge of finding a cure for HIV infection. Science 323:1304-1307.
14. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF. 2012. Stimulation of HIV-1specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36:491-501.
15. Antinori A, Perno CF, Giancola ML, Forbici F, Ippolito G, Hoetelmans RM, Piscitelli SC. 2005. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin. Infect. Dis. 41:1787-1793.
16. Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. 2003. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47:238-243.
17. Valentin A, Morrow M, Poirier RH, Aleman K, Little R, Yarchoan R, Pavlakis GN. 2010. Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells. AIDS Res. Hum. Retroviruses 26:79-88.
18. Contreras-Galindo R, Almodovar-Camacho S, Gonzalez-Ramirez S, Lorenzo E, Yamamura Y. 2007. Comparative longitudinal studies of HERV-K and HIV-1 RNA titers in HIV-1-infected patients receiving successful versus unsuccessful highly active antiretroviral therapy. AIDS Res. Hum. Retroviruses 23:1083-1086.
19. Contreras-Galindo R, Kaplan MH, Contreras-Galindo AC, GonzalezHernandez MJ, Ferlenghi I, Giusti F, Lorenzo E, Gitlin SD, Dosik MH, Yamamura Y, Markovitz DM. 2012. Characterization of human endogenous retroviral elements in the blood of HIV-1-infected individuals. J. Virol. 86:262-276.
20. Marini A, Harper JM, Romerio F. 2008. An in vitro system to model the establishment and reactivation of HIV-1 latency. J. Immunol. 181:7713-7720.
21. Adkins D, Ratanatharathorn V, Yang H, White B. 2009. Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease. Transplantation 88:198-202.
22. Besse T, Malaise J, Mourad M, Pirson Y, Hope J, Awwad M, WhiteScharf M, Squifflet JP. 1997. Prevention of rejection with BTI-322 after renal transplantation (results at 9 months). Transplant. Proc. 29:2425-2426.
23. Bissonnette R, Langley RG, Papp K, Matheson R, Toth D, Hultquist M, Geba GP, White B. 2009. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab. Arch. Dermatol. Res. 301:429-442.
24. Brochstein JA, Grupp S, Yang H, Pillemer SR, Geba GP. 2010. Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease. Pediatr. Transplant. 14:233-241.
25. Fanale MA, Younes A. 2007. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 67:333-350.
26. Mourad M, Besse T, Malaise J, Baldi A, Latinne D, Bazin H, Pirson Y, Hope J, Squifflet JP. 1997. BTI-322 for acute rejection after renal transplantation. Transplant. Proc. 29:2353. doi:10.1016/S0041-1345(97)00398-9.
27. O'Mahony D, Morris JC, Stetler-Stevenson M, Matthews H, Brown MR, Fleisher T, Pittaluga S, Raffeld M, Albert PS, Reitsma D, Kaucic K, Hammershaimb L, Waldmann TA, Janik JE. 2009. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin. Cancer Res. 15:2514-2522.
28. Pruett TL, McGory RW, Wright FH, Pescovitz MD, Yang H, McClain JB. 2009. Safety profile, pharmacokinetics, and pharmacodynamics of siplizumab, a humanized anti-CD2 monoclonal antibody, in renal allograft recipients. Transplant. Proc. 41:3655-3661.
29. Przepiorka D, Phillips GL, Ratanatharathorn V, Cottler-Fox M, Sehn LH, Antin JH, LeBherz D, Awwad M, Hope J, McClain JB. 1998. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 92:4066-4071.
30. Squifflet JP, Besse T, Malaise J, Mourad M, Delcorde C, Hope JA, Pirson Y. 1997. BTI-322 for induction therapy after renal transplantation: a randomized study. Transplant. Proc. 29:317-319.
31. Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA. 2003. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood 102:284-288.
32. Iglesias-Ussel MD, Marchionni L, Romerio F. 20 February 2013. Isolation of microarray-quality RNA from primary human cells after intracellular immunostaining and fluorescence-activated cell sorting. J. Immunol. Methods doi:10.1016/j.jim.2013.02.003.
33. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, Davie JR, Shi Y, Hansen U, Margolis DM. 2000. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J. Virol. 74:6790-6799.
34. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
35. Ruhl M, Himmelspach M, Bahr GM, Hammerschmid F, Jaksche H, Wolff B, Aschauer H, Farrington GK, Probst H, Bevec D, Hauber J. 1993. Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating transactivation. J. Cell Biol. 123:1309-1320.
36. Modiano JF, Domenico J, Szepesi A, Lucas JJ, Gelfand EW. 1994. Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T cells. J. Biol. Chem. 269:32972-32978.
37. Utley RT, Cote J. 2003. The MYST family of histone acetyltransferases. Curr. Top. Microbiol. Immunol. 274:203-236.
38. Henderson BR, Percipalle P. 1997. Interactions between HIV Rev and nuclear import and export factors: the Rev nuclear localisation signal mediates specific binding to human importin-beta. J. Mol. Biol. 274:693-707.
39. Arnold M, Nath A, Hauber J, Kehlenbach RH. 2006. Multiple importins function as nuclear transport receptors for the Rev protein of human immunodeficiency virus type 1. J. Biol. Chem. 281:20883-20890.
40. Gautier VW, Gu L, O'Donoghue N, Pennington S, Sheehy N, Hall WW. 2009. In vitro nuclear interactome of the HIV-1 Tat protein. Retrovirology 6:47. doi:10.1186/1742-4690-6-47.
41. Bosque A, Planelles V. 2009. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113:58-65.
42. Burke B, Brown HJ, Marsden MD, Bristol G, Vatakis DN, Zack JA. 2007. Primary cell model for activation-inducible human immunodeficiency virus. J. Virol. 81:7424-7434.
43. Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, Arkin AP. 2010. Combinatorial latency reactivation for HIV-1 subtypes and variants. J. Virol. 84:5958-5974.
44. Gondois-Rey F, Biancotto A, Pion M, Chenine AL, Gluschankof P, Horejsi V, Tamalet C, Vigne R, Hirsch I. 2001. Production of HIV-1 by resting memory T lymphocytes. AIDS 15:1931-1940.
45. Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC. 2012. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One 7:e30176. doi:10.1371/journal .pone.0030176.
46. Sahu GK, Lee K, Ji J, Braciale V, Baron S, Cloyd MW. 2006. A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes. Virology 355:127-137.
47. Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. 2007. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 110:4161-4164.
48. Swiggard WJ, Baytop C, Yu JJ, Dai J, Li C, Schretzenmair R, Theodosopoulos T, O'Doherty U. 2005. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J. Virol. 79:14179-14188.
49. Tyagi M, Pearson RJ, Karn J. 2010. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 84:6425-6437.
50. Yang HC, Xing S, Shan L, O'Connell K, Dinoso J, Shen A, Zhou Y, Shrum CK, Han Y, Liu JO, Zhang H, Margolick JB, Siliciano RF. 2009. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 119:3473-3486.
51. Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV. 2009. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One 4:e8490. doi:10.1371/journal.pone.0008490.
52. Bradley LM, Haynes L, Swain SL. 2005. IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol. 26:172-176.
53. Khaled AR, Durum SK. 2003. Death and Baxes: mechanisms of lymphotrophic cytokines. Immunol. Rev. 193:48-57.
54. Swain SL, Agrewala JN, Brown DM, Jelley-Gibbs DM, Golech S, Huston G, Jones SC, Kamperschroer C, Lee WH, McKinstry KK, Roman E, Strutt T, Weng NP. 2006. CD4+ T-cell memory: generation and multifaceted roles for CD4+ T cells in protective immunity to influenza. Immunol. Rev. 211:8-22.
55. de la Fuente C, Santiago F, Deng L, Eadie C, Zilberman I, Kehn K, Maddukuri A, Baylor S, Wu K, Lee CG, Pumfery A, Kashanchi F. 2002. Gene expression profile of HIV-1 Tat expressing cells: a close interplay between proliferative and differentiation signals. BMC Biochem. 3:14. doi: 10.1186/1471-2091-3-14.
56. Krishnan V, Zeichner SL. 2004. Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency. J. Virol. 78:9458-9473.
57. Munier S, Delcroix-Genete D, Carthagena L, Gumez A, Hazan U. 2005. Characterization of two candidate genes, NCoA3 and IRF8, potentially involved in the control of HIV-1 latency. Retrovirology 2:73. doi:10.1186 /1742-4690-2-73.
58. Bandyopadhyay S, Kelley R, Ideker T. 2006. Discovering regulated networks during HIV-1 latency and reactivation. Pac. Symp. Biocomput. 2006:354-366.
59. Chun TW, Justement JS, Lempicki RA, Yang J, Dennis G, Jr, Hallahan CW, Sanford C, Pandya P, Liu S, McLaughlin M, Ehler LA, Moir S, Fauci AS. 2003. Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc. Natl. Acad. Sci. U. S. A. 100:1908-1913.
60. Mbonye U, Karn J. 2011. Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr. HIV Res. 9:554-567.
61. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. 2009. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 5:e1000495. doi:10.1371/journal.ppat.1000495.
62. Brooks DG, Zack JA. 2002. Effect of latent human immunodeficiency virus infection on cell surface phenotype. J. Virol. 76:1673-1681.
63. Chen BK, Gandhi RT, Baltimore D. 1996. CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J. Virol. 70:6044-6053.
64. Chugh P, Bradel-Tretheway B, Monteiro-Filho CM, Planelles V, Maggirwar SB, Dewhurst S, Kim B. 2008. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology 5:11. doi:10.1186 /1742-4690-5-11.
65. Chugh P, Fan S, Planelles V, Maggirwar SB, Dewhurst S, Kim B. 2007. Infection of human immunodeficiency virus and intracellular viral Tat protein exert a pro-survival effect in a human microglial cell line. J. Mol. Biol. 366:67-81.
66. Emerman M, Malim MH. 1998. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 280:1880-1884.
67. Poon B, Grovit-Ferbas K, Stewart SA, Chen IS. 1998. Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents. Science 281:266-269.
68. Selliah N, Finkel TH. 2001. Biochemical mechanisms of HIV induced T cell apoptosis. Cell Death Differ. 8:127-136.
69. Tanaka M, Ueno T, Nakahara T, Sasaki K, Ishimoto A, Sakai H. 2003. Downregulation of CD4 is required for maintenance of viral infectivity of HIV-1. Virology 311:316-325.
70. Bastiani L, Laal S, Kim M, Zolla-Pazner S. 1997. Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J. Virol. 71:3444-3450.
71. Meuer SC, Hussey RE, Fabbi M, Fox D, Acuto O, Fitzgerald KA, Hodgdon JC, Protentis JP, Schlossman SF, Reinherz EL. 1984. An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell 36:897-906.
72. Bressler P, Pantaleo G, Demaria A, Fauci AS. 1991. Anti-CD2 receptor antibodies activate the HIV long terminal repeat in T lymphocytes. J. Immunol. 147:2290-2294.
73. Shen A, Yang HC, Zhou Y, Chase AJ, Boyer JD, Zhang H, Margolick JB, Zink MC, Clements JE, Siliciano RF. 2007. Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J. Virol. 81:1660-1670.
74. Cooper JC, Morgan G, Harding S, Subramanyam M, Majeau GR, Moulder K, Alexander DR. 2003. Alefacept selectively promotes NK cell-mediated deletion of CD45R0 + human T cells. Eur. J. Immunol. 33:666-675.
75. Nizet Y, Chentoufi AA, de la Parra B, Lewalle P, Rouas R, Cornet A, Besse T, Mourad M, Malaise J, Squifflet JP, Bazin H, Latinne D. 2000. The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322. Transplantation 69:1420-1428.
76. da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS. 2002. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J. Immunol. 168:4462-4471.
77. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. 1994. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J. Immunol. 152:2753-2767.
78. Algino KM, Thomason RW, King DE, Montiel MM, Craig FE. 1996. CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. Am. J. Clin. Pathol. 106:78-81.
79. Withers DR, Fiorini C, Fischer RT, Ettinger R, Lipsky PE, Grammer AC. 2007. T cell-dependent survival of CD20+ and CD20 - plasma cells in human secondary lymphoid tissue. Blood 109:4856-4864.
80. Aggarwal BB, Gupta SC, Kim JH. 2012. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119:651-665.
81. Herbein G, O'Brien WA. 2000. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc. Soc. Exp. Biol. Med. 223:241-257.
82. Denoeud J, Moser M. 2011. Role of CD27/CD70 pathway of activation in immunity and tolerance. J. Leukoc. Biol. 89:195-203.
83. Park GB, Kim YS, Lee HK, Song H, Cho DH, Lee WJ, Hur DY. 2010. Endoplasmic reticulum stress-mediated apoptosis of EBV-transformed B cells by cross-linking of CD70 is dependent upon generation of reactive oxygen species and activation of p38 MAPK and JNK pathway. J. Immunol. 185:7274-7284.
84. Berndt C, Mopps B, Angermuller S, Gierschik P, Krammer PH. 1998. CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells. Proc. Natl. Acad. Sci. U. S. A. 95:12556-12561.
85. Trushin SA, Algeciras-Schimnich A, Vlahakis SR, Bren GD, Warren S, Schnepple DJ, Badley AD. 2007. Glycoprotein 120 binding to CXCR4 causes p38-dependent primary T cell death that is facilitated by, but does not require cell-associated CD4. J. Immunol. 178:4846-4853.